Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources
Home/Rare Diseases/Alagille Syndrome

Liver & Hepatic

Alagille Syndrome (ALGS) Clinical Trials and Treatments

Also called Alagille-Watson syndrome, ALGS, hepatic ductular hypoplasia, Alagilles Syndrome

Alagille syndrome (ALGS) is an autosomal dominant multi-system disorder caused by mutations in the JAG1 or NOTCH2 genes, which regulate the Notch signaling pathway critical for normal organ development and tissue maintenance throughout life. The hallmark hepatic feature is intrahepatic bile duct hypoplasia, characterized by a decreased number of interlobular bile ducts with progressive obliteration of remaining ducts leading to cholestasis and progressive liver disease.

In plain words, Alagille syndrome is a genetic condition where the liver has too few of the tiny tubes that drain bile, a digestive fluid. Bile backs up in the liver and the condition can also affect the heart, bones, eyes and face.

Get an email when new Alagille Syndrome trials open or the FDA decides. Get alerts

Alagille Syndrome

Where treatments stand, from ClinicalTrials.gov and FDA labels

Also 6 studies with no phase, like observational studies, and 1 phase 4 study following medicines after approval.

FDA review0

No decision pending. FDA calendar

FDA-approved medicines2

Bylvay · Livmarli

Alagille Syndrome has 2 FDA-approved medicines, 7 open or active clinical trials (7 recruiting), and no pending FDA decision.

Labels checked October 21, 2026. Corticosteroids and immune globulins count once each.Download the data

Latest for Alagille Syndrome

See all trialsThe week in rare disease

Each date is the day a change was posted. Open an item to see where things stand now.

More about Alagille Syndrome

Cardiac involvement occurs in approximately 90% of patients, most commonly manifesting as pulmonary stenosis or other right-sided heart lesions. The characteristic facial features include a broad forehead, pointed chin, hypertelorism (widely-spaced eyes), and straight nose that become more apparent with age. Skeletal abnormalities including butterfly vertebrae and scoliosis are common and may cause functional limitations. Ocular abnormalities such as posterior embryotoxon and retinal pigmentary changes, along with hearing loss, occur in variable proportions.

Keep reading about Alagille Syndrome

Notably, disease severity varies dramatically among affected individuals: some patients maintain relatively normal liver function into adulthood with minimal symptoms, while others develop progressive cirrhosis with portal hypertension, esophageal varices, and liver failure requiring transplantation by late childhood. This remarkable variability in phenotype is even observed within families carrying the same mutation.

What are the symptoms of Alagille Syndrome?

These are common symptoms of Alagille Syndrome, and how strong they are varies from person to person.

  • Cholestasis and jaundice in infancy
  • Bile duct hypoplasia and progressive liver disease
  • Cardiac defects including pulmonary stenosis
  • Characteristic facial features
  • Skeletal abnormalities and butterfly vertebrae
  • Hearing loss and eye abnormalities

Who gets Alagille Syndrome?

Alagille syndrome typically manifests in infancy with cholestasis presenting as jaundice and pale stools, though age of onset and severity vary considerably.

The condition affects males and females equally. Since it follows autosomal dominant inheritance, approximately 50% of children born to an affected parent inherit the condition. Both familial cases and de novo mutations occur. Expression is highly variable with incomplete penetrance, meaning some carriers of mutations have minimal or no clinical manifestations while others develop severe multisystem disease.

Next steps: find trials you might fitsee approved treatmentsget help payingget alerts

Which medicines are FDA-approved for Alagille Syndrome?

There are currently 2 FDA-approved medications for Alagille Syndrome.

odevixibat
Ipsen Biopharmaceuticals, Inc.
Search
maralixibat chloride
Mirum Pharmaceuticals Inc.
Search

Source: openFDA drug labeling data. This list may not include all treatments. Always consult your doctor.

How to get help paying for Alagille Syndrome treatment

Charity funds and drugmaker programs for Alagille Syndrome, checked at the source.

Which insurance do you have? Pick one to see what fits. Tap it again to clear.
Your insurance
Charity funds
  • From a charity · Alagille Syndrome Alliance
    ALGSAssistance Program fund
    Open

    Pays for: Rent or mortgage, utilities, insurance premiums, counseling, and medical, adaptive or mobility equipment, up to $1,000 per year.

    The foundation says: “Apply now (reviewed case by case as funding allows)”
  • From a charity · HealthWell Foundation
    Alagille Syndrome Vitamins and Supplements fund
    Open

    Pays for: Copays, premiums or other treatment costs.

Status as each foundation showed it on November 16, 2026.
Drugmaker programs
Open a medicine for who qualifies, by insurance type.

Every program and fund for Alagille Syndrome, by insurance →

Side effects people have reported to the FDA

Side effects people have reported to the FDA

Real-world side effect reports from the FDA Adverse Event Reporting System (FAERS). Includes both FDA-approved drugs and investigational therapies from active clinical trials. Click any drug to see what patients reported.

Loading side effect data...

Diagnosis and genetic testing

Genetic testing for Alagille Syndrome

Genetic testing can confirm a diagnosis, guide treatment decisions, and identify family members who may be at risk.

Finding labs...

Trusted Alagille Syndrome resources

Reputable organizations and medical references for learning more about Alagille Syndrome, including disease registries, foundation resources, and clinical guidelines.

Active clinical trials for Alagille Syndrome

Use this Alagille Syndrome clinical trial finder to see the 7 studies recruiting patients in the United States and worldwide, with eligibility criteria in plain English. Of these, 1 tests a treatment and 6 are observational studies or registries; each card says which. Every trial comes from ClinicalTrials.gov.

Jump to the trial list, the site map or the pipeline timeline.

Note: Trial recruitment statuses on ClinicalTrials.gov may not immediately reflect recent FDA decisions, sponsor announcements, or enrollment changes. Always confirm a trial's current status directly with the study coordinator before making plans.

7 active trials worldwide
Filter:
Sort:
RecruitingObservational study, no treatment givenRecently updatedNCT06193928

Long-Term SafEty and Clinical Outcomes of LivmArli in Patients in the United States (LEAP-US)

Intervention: Livmarli, Livmarli

Sponsor: Mirum Pharmaceuticals, Inc.

The objective of this 5-year, prospective, observational cohort study is to evaluate the long-term safety and clinical outcomes of patients with Alagille syndrome (ALGS) or Progressive familial intrahepatic cholestasis (PFIC) treated with Livmarli.

Ages not specified
Started Sep 2023Updated 5 days agoEst. Sep 2028 (~1y 10m)
RecruitingPatient registry covering many conditionsRecently updatedNCT01793168

Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford

Sponsor: Sanford Health

The Coordination of Rare Diseases at Sanford (CoRDS) is an international patient registry that serves as a centralized resource for rare disease research. Individuals affected by rare diseases, undiagnosed conditions, and disorders of unknown prevalence may voluntarily contribute...

Ages not specified1 location
Started Jul 2010Updated 3 weeks agoEst. Dec 2100 (~74y 2m)
RecruitingObservational study, no treatment givenRecently updatedNCT06850038

A Study Observing the Long-term, Effectiveness and Safety of Odevixibat (Bylvay) in Patients With Alagille Syndrome (ALGS) Who Are Receiving Ongoing Treatment

Sponsor: Ipsen

This study will collect information from patients with Alagille syndrome (ALGS) as they use odevixibat (Bylvay) in their daily lives.

Odevixibat is a medicine that helps patients with ALGS, a rare disease that harms their liver and causes itching.

Ages not specified
Started Apr 2025Updated 3 weeks agoEst. Nov 2030 (~4 years)
RecruitingObservational study, no treatment givenRecently updatedNCT07585097

A Study to Observe the Long-term Safety of Odevixibat in Patients With Alagille Syndrome (ALGS) Who Are Receiving Ongoing Treatment

Sponsor: Ipsen

This study will collect information from patients with ALGS who are using odevixibat in their daily lives. Odevixibat is a medication that helps patients with ALGS, a rare disease that affects the liver and causes itching.

Ages 6 Months+
Started Jul 2026Updated 3 weeks agoEst. Sep 2031 (~4y 10m)
RecruitingObservational study, no treatment givenRecently updatedNCT07411716

Pediatric Evaluation and Registry for Liver Cholestasis in Canada

Sponsor: Children's Hospital of Eastern Ontario · Mirum Pharmaceuticals, Inc.

The purpose of this study is to create a national, multi-centre registry for children with Alagille syndrome (ALGS) and Genetic Intrahepatic Cholestasis (GIC) that follows participants long-term, ensuring standardized, high-quality data capture across all participating pediatric hepatology centres.

Ages up to 18 Years
Started Apr 2026Updated 1 month agoEst. Mar 2031 (~4y 4m)
Find Alagille Syndrome trials near you, ranked by distance →
Active trial locations15 cities in the US
A study site. Select it to see its trials and get directions. Several sites close together. Select the number to zoom in.
+7 more

Trial Pipeline

Jan 2021 to Nov 2031
2021
2023
2025
2027
2029
2031
now
Phase 4
Observational
RecruitingNot yet recruitingDelayed startTodayHover a bar for trial details

Read more about Alagille Syndrome trials

Need help understanding these trials?
Answers with sources, in plain English
Start withor ask
Run an Alagille Syndrome foundation or patient group?
You can put this live trial list on your own website. It updates itself, and it's free.
Get the embed code →

Data from ClinicalTrials.gov, U.S. National Library of Medicine.
Always talk to your doctor before considering a clinical trial.

Alagille Syndrome patient communities

Facebook groups, Reddit communities and YouTube channels where Alagille Syndrome patients, caregivers and advocacy groups talk.

Companies developing Alagille Syndrome treatments

Drugmakers that list Alagille Syndrome in their rare disease portfolio, 3 in all.

Questions people ask about Alagille Syndrome